1. Dugbartey AT, Barimah KB. Traditional beliefs and knowledge base about epilepsy among university students in Ghana. Ethnicity & Disease. 2013;23(1):1-5.
2. Forsgren LA. Incidence and prevalence. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London, UK: Arnold; 2004. P. 21-5. [
DOI:10.1201/b13560-4]
3. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, et al. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA therapy not only in young children. Seizure. 2006;15(6):443-8. [
DOI:10.1016/j.seizure.2006.05.007] [
PMID]
4. Gerstner T, Bauer MO, Longin E, Bell N, Koenig SA. Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2-year-old girl. Seizure. 2007;16(6):554-6. [
DOI:10.1016/j.seizure.2007.04.003] [
PMID]
5. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 12th ed. New York, NY: McGraw-Hill; 2012. P. 426.
6. Shorvon S. Pyrrolidone derivatives. The Lancet. 2001;358(9296):1885-92. [
DOI:10.1016/S0140-6736(01)06890-8] [
PMID]
7. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics. 2004;43(11):707-24. [
DOI:10.2165/00003088-200443110-00002] [
PMID]
8. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences. 2004;101(26):9861-6. [
DOI:10.1073/pnas.0308208101] [
PMID] [
]
9. Nowack A, Malarkey EB, Yao J, Bleckert A, Hill J, Bajjalieh SM. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One. 2011;6(12):e29560. [
DOI:10.1371/journal.pone.0029560] [
PMID] [
]
10. Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Frontiers in Neurology. 2014;5:11. [
DOI:10.3389/fneur.2014.00011] [
PMID] [
]
11. :union: Chimique Belge (UCB). Keppra (levetiracetam 250, 500, 750 and, 1000 mg tablets and 100 mg/ml for solution of infusion): summary of product characteristics. London: European Medicine Agency; 2010.
12. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Research. 1999;34(2-3):161-8. [
DOI:10.1016/S0920-1211(98)00104-1] [
PMID]
13. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Clinical Pharmacokinetics. 1996;31(1):29-46. [
DOI:10.2165/00003088-199631010-00003] [
PMID]
14. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacology & Therapeutics. 1995;67(3):351-84. [
DOI:10.1016/0163-7258(95)00021-6] [
PMID]
15. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42(12):1574-9. [
DOI:10.1046/j.1528-1157.2001.41300.x] [
PMID]
16. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure. 2004;13(3):142-5. [
DOI:10.1016/S1059-1311(03)00193-6] [
PMID]
17. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure. 2005;14(1):66-71. [
DOI:10.1016/j.seizure.2004.10.004] [
PMID]
18. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654-60. [
DOI:10.1212/01.wnl.0000217916.00225.3a] [
PMID]
19. Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. European Journal of Paediatric Neurology. 2008;12(4):321-7. [
DOI:10.1016/j.ejpn.2007.09.004] [
PMID]
20. Chung AM, Eiland LS. Use of second-generation antiepileptic drugs in the pediatric population. Pediatric Drugs. 2008;10(4):217-54. [
DOI:10.2165/00148581-200810040-00003] [
PMID]
21. Van de Vrie-Hoekstra NW, De Vries TW, Van den Berg PB, Brouwer OF, De Jong-Van Den Berg LT. Antiepileptic drug utilization in children from 1997-2005-a study from the Netherlands. European Journal of Clinical Pharmacology. 2008;64(10):1013-20. [
DOI:10.1007/s00228-008-0480-z] [
PMID]
22. Legros B, Boon P, De Jonghe P, Sadzot B, Van Rijckevorsel K, Schmedding E. Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET‐2). Acta Neurologica Scandinavica. 2009;120(6):402-10. [
DOI:10.1111/j.1600-0404.2009.01182.x] [
PMID]
23. Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia. 2010;51(5):789-96. [
DOI:10.1111/j.1528-1167.2009.02331.x] [
PMID]
24. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. Journal of Child Neurology. 2008;23(5):515-9. [
DOI:10.1177/0883073807309784] [
PMID]
25. Barr D, Pranske Z, Castillo R, Kirmani B. Efficacy and tolerability of intravenous levetiracetam as monotherapy in acute seizure management in children. Neurology. 2018;90(15):289. [
DOI:10.1212/WNL.90.15_supplement.P5.289]
26. Weijenberg A, Brouwer OF, Callenbach PM. Levetiracetam monotherapy in children with epilepsy: a systematic review. CNS Drugs. 2015;29(5):371-82. [
DOI:10.1007/s40263-015-0248-9] [
PMID] [
]
27. Egunsola O, Choonara I, Sammons HM. Safety of levetiracetam in paediatrics: a systematic review. PloS One. 2016;11(3):e0149686. [
DOI:10.1371/journal.pone.0149686] [
PMID] [
]
28. Yaghhini O, Nasiri J, Nasr IP. Study of sodium valproate's side effects in 2 to 15-year-old children withepilepsy or migraine disorders. Journal of Isfahan Medical School. 2017;34(387):707-11.
29. Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz‐Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta‐analysis. Epilepsia. 2011;52(7):1280-91. [
DOI:10.1111/j.1528-1167.2011.03047.x] [
PMID]
30. Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the quality standards subcommittee of the American Academy of Neurology and the Ad Hoc task force of the commission on therapeutic strategies of the international league against epilepsy. Neurology. 2012;78(2):139-45. [
DOI:10.1212/WNL.0b013e31823efcf8] [
PMID] [
]
31. Tanaka S, Tanaka T. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Epileptic Disorders. 2013;15(2):132-41. [
DOI:10.1684/epd.2013.0576] [
PMID]
32. Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Pharmacology. 1995;286(2):137-46. [
DOI:10.1016/0014-2999(95)00436-O] [
PMID]
33. Wu Xy, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, et al. Multicenter double-blind, randomized, placebocontrolled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia. 2009;50(3):398-405. [
DOI:10.1111/j.1528-1167.2008.01729.x] [
PMID]
34. Cataldi M, Lariccia V, Secondo A, Di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1, 4, 5-trisphosphate-dependent [Ca2+] I increase induced by ATP and bradykinin in PC12 cells. Journal of Pharmacology and Experimental Therapeutics. 2005;313(2):720-30. [
DOI:10.1124/jpet.104.079327] [
PMID]
35. El Sabaa RM, Hamdi E, Hamdy NA, Sarhan HA. Effects of levetiracetam compared to valproate on cognitive functions of patients with epilepsy. Neuropsychiatric Disease and Treatment. 2020;16:1945. [
DOI:10.2147/NDT.S256117] [
PMID] [
]